Thrombofilia, inflammation and markers of cardiovascular disease in HIV-1 infected patients

Completed

• Conditions: coagulation factors; venous thrombosis; 10064477; 10047438; 10014523

• Registration Number: NL-OMON34363
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Patients with active HIV-1 infection who have an indication for starting treatment with cART
18 years or older of age

Exclusion Criteria

Patients with HIV-1 infection al ready on cART
HIV-2 infection
Pregnancy
Oral contraception
Not able to understand Dutch lor English anguage

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Measurement of the levels of the following thrombophilic factors including:<br /><br>anti-thrombin, protein C, protein S, free protein S, fibrinogen, lupus<br /><br>anticoagulant, von Willebrand factor, factor VIII and D-dimer, at four moments<br /><br>in time after starting with cART and comparing those levels with baseline to<br /><br>determine changes. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Measurement of the levels of the following thrombophilic factors including:<br /><br>CRP, hsCRP, Cholesterol, HDL- and LDL-cholesterol, triglycerides, at four<br /><br>moments in time after starting with cART and comparing those levels with<br /><br>baseline to determine changes. </p><br>